Skip to main content

Tumor Angiogenesis

Edited by Francesco Pezzella and Chao-Nan Qian

Forming efficient vasculature network, also known as tumor angiogenesis, is a critical hallmark in tumor development. Explorations on its underlying molecular mechanisms have resulted in several novel anti-cancer drugs approved by the Food & Drug Administration (FDA) of the United States. However, the modest survival benefits from anti-angiogenic therapy have forced us to revisit our understanding on tumor angiogenesis. In this special issue of the Chinese Journal of Cancer (CJC), the world leading experts in pathology, molecular biology, pharmacology, and clinical study have contributed their critical thoughts and insightful investigations from different angles to reveal the alternative tumor angiogenesis approaches and potential treatment targets. This special issue is therefore initiating a new era in tumor angiogenesis research, aiming to develop next-generation anti-angiogenic targeted therapy.

This series was published in Chinese Journal of Cancer.

  1. Validated preclinical studies have provided evidence that anti-vascular endothelial growth factor (VEGF) compounds enhance the activity of subsequent antitumor therapy, but the mechanism of this potentiation i...

    Authors: Ilaria Fuso Nerini, Marta Cesca, Francesca Bizzaro and Raffaella Giavazzi
    Citation: Chinese Journal of Cancer 2016 35:61
  2. The limited clinical benefits from current antiangiogenic therapy for cancer patients have triggered some critical thoughts and insightful investigations aiming to further elucidate the relationship between ve...

    Authors: Francesco Pezzella, Kevin Gatter and Chao-Nan Qian
    Citation: Chinese Journal of Cancer 2016 35:22
  3. In human patients, drugs that block tumor vessel growth are widely used to treat a variety of cancer types. Many rigorous phase 3 clinical trials have demonstrated significant survival benefits; however, the a...

    Authors: Yihai Cao
    Citation: Chinese Journal of Cancer 2016 35:21
  4. Directed capillary ingrowth has long been considered synonymous with tumor vascularization. However, the vasculature of primary tumors and metastases is not necessarily formed by endothelial cell sprouting; in...

    Authors: Edina Bugyik, Ferenc Renyi-Vamos, Vanessza Szabo, Katalin Dezso, Nora Ecker, Andras Rokusz, Peter Nagy, Balazs Dome and Sandor Paku
    Citation: Chinese Journal of Cancer 2016 35:19
  5. Angiogenesis is not essential for tumours to develop and expand, as cancer can also grow in a non-angiogenic fashion, but why this type of growth occurs is unknown. Surprisingly, our data from mRNA transcripti...

    Authors: Omanma Adighibe, Russell D. Leek, Marta Fernandez-Mercado, Jiangting Hu, Cameron Snell, Kevin C. Gatter, Adrian L. Harris and Francesco Pezzella
    Citation: Chinese Journal of Cancer 2016 35:18
  6. Endostatin (ES) is a well-established potent endogenous antiangiogenic factor. An ES variant, called zinc-binding protein-ES (ZBP-ES), is clinically available; however, its use is limited by rapid renal cleara...

    Authors: Shan Wang, Yan Fu and Yongzhang Luo
    Citation: Chinese Journal of Cancer 2016 35:14
  7. Tumor growth and metastasis depend on the establishment of tumor vasculature to provide oxygen, nutrients, and other essential factors. The well-known vascular endothelial growth factor (VEGF) signaling is cru...

    Authors: Chao-Nan Qian, Min-Han Tan, Jun-Ping Yang and Yun Cao
    Citation: Chinese Journal of Cancer 2016 35:10